

MOLECULAR BASIS FOR RESISTANCE TO TARGETED AGENTS

Co-Chairmen: Richard Marais, William Sellers, David Livingston, Enrico Mihich

Thursday, June 14, 2012

8:15	Registration	
8:45	President	Welcome
8:50	Enrico Mihich	Introduction
9:00	David Livingston	Focus & Goals
9:15	Jeffrey Engelman	Keynote Address: Challenges in overcoming resistance to kinase inhibitors

Session I, Genetics of Resistance I

Chair/Moderator: Lewis Chodosh

10:00	Lewis Chodosh	Mechanisms of tumor dormancy and recurrence
10:25	Discussion	
10:45	Coffee Break	
11:05	Elaine Mardis	Genomic exploration of therapy resistance
11:30	Discussion	
11:50	Thomas O'Hare	Compounding the problem of clinical resistance to TKIs in CML
12:15	Discussion	
12:35	Levi Garraway	Defining the spectrum of resistance to targeted anticancer agents
13:00	Discussion	
13:20	Lunch	

Session II, Clinical Advances in Overcoming Resistance

Chair/Moderator: Jose Baselga

14:30	Jose Baselga	Reverting endocrine resistance by targeting the mTOR pathway:
14:55	Discussion	A new paradigm in the therapy of breast cancer
15:15	Jeff Sosman	Clinical approaches to BRAF inhibitor resistance in melanoma
15:40	Discussion	
16:00	Johan deBono	Improving outcome from prostate cancer
16:25	Discussion	
16:45	Adjourn	

Friday, June 15, 2012

Session III, Resistance through Perturbed Signaling

Chair/Moderator: Richard Marais

8:30	Richard Marais	BRAF and RAS signaling in cancer; translating basic
8:55	Discussion	understanding into clinical benefit
9:15	Alberto Bardelli	Mechanisms of resistance to EGFR targeted therapies
9:40	Discussion	in colorectal cancer
10:00	Coffee Break	
10:20	Neal Rosen	Adaptive resistance to oncoprotein inhibition
10:45	Discussion	
11:05	Rafaella Sordella	Intrinsic and extrinsic mechanisms of erlotinib resistance in NSCLC
11:30	Discussion	
11:50	Poster Session & Lunch	

Session IV, Genetics of Resistance II

Chair/Moderator: William Sellers

14:00	William Sellers	Approaches to the discovery and treatment of therapeutic resistance
14:25	Discussion	
14:45	Jos Jonkers	Studying therapy response and resistance in mouse models
15:10	Discussion	BRCA-associated breast cancer
15:30	Roman Thomas	Lung cancer genomics
15:55	Discussion	
16:25	Giulio Superti-Furga	Effectors and targets of anticancer agents
16:50	Discussion	
17:10	Silvia Buonamici	Identifying the mechanisms of resistance to smoothed inhibitors
17:35	Discussion	
17:50	Adjourn	
20:00	Symposium Dinner	

Saturday, June 16, 2012

8:00 Best Posters' Oral Presentations

Session V, Role of the Tumor Microenvironment in Resistance

Chair/Moderator: David Tuveson

9:00	David Tuveson	The pancreatic tumor stroma influences therapeutic response
9:25	Discussion	
9:45	Ben Stanger	The dynamics of primary tumor spread in pancreatic cancer
10:10	Discussion	
10:30	James Allison	Immune checkpoint blockade: New insights and opportunities
10:50	Discussion	
11:20	Todd Golub	Systematic approaches to discovering microenvironment-
11:45	Discussion	mediated drug resistance
12:05	David Livingston	Concluding Remarks
12:30	Lunch & Adjourn	